The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).

In this study we will describe

• habits of medical staff in prescription of growth factors or antibiotic prophylaxis
• ratio of patients treated by growth factors in primary or secondary prophylaxis
• ratio of patients treated in primary prophylaxis who present a febrile neutropenia
• ratio of patients who need to be hospitalized and the duration of those hospitalizations.
• causes of lateness, of decreasing, and of stop of chemotherapy
• antibiotic and growth factors prophylaxis tolerance .

Inclusion Criteria:

• patients with histologically proved head and neck squamous cell carcinoma
• age: more than 18
• patients who are beginning a chemotherapy (docetaxel+cisplatin+ 5FU)
• patients must have been informed of automatic data processing concerning them.

Exclusion Criteria:

• previous chemotherapy for the head and neck squamous cell carcinoma
• previous chemotherapy for an other cancer in the two years before
• intercurrent illness that could significantly interfere with chemotherapy such as HIV infection, infection or active febrile illness, a chronic intestinal disease

people who undergo first traitement by chemotherapy (docetaxel+cisplatin+-FU) for head and neck cell carcinoma, whom age is over eighteen,